Odyssey Therapeutics Stock Forecast
NASDAQ: ODTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
ODTX analyst consensus
Consensus (6 analysts)
none
Avg. price target
$35.75+97.30%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Odyssey Therapeutics (2026-10-08), 6 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $35.75, with a high estimate of $44.00 and a low estimate of $29.00. The average target implies upside of 97.3% from the current price of $18.12.
The spread between the highest and lowest targets is 51.7%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ODTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 17% |
| Buy | 5 | 83% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $29.00 | +60.04% |
| Average target | $35.75 | +97.30% |
| High target | $44.00 | +142.83% |